|
|
Post by brentie on Jan 24, 2019 12:16:13 GMT -5
Norwegian scientists discover new small molecule drug to treat prostate cancer "The drug MKC8866 is a small molecule belonging to a group of substances called hydroxy-aryl-aldehydes. It has been developed by the originally US-based biotech company MannKind Corporation, which has screened a total of about 200,000 chemical substances to find MKC8866. Professor Saatcioglus's research group has documented that MKC8866 counteracts the growth of prostate cancer tumors and shown that it interferes with a kind of chain reaction - a signaling pathway - that is associated with the cells' stress response." www.news-medical.net/news/20190124/Norwegian-scientists-discover-new-small-molecule-drug-to-treat-prostate-cancer.aspx |
|
|
|
Post by esstan2001 on Jan 24, 2019 12:27:24 GMT -5
Norwegian scientists discover new small molecule drug to treat prostate cancer "The drug MKC8866 is a small molecule belonging to a group of substances called hydroxy-aryl-aldehydes. It has been developed by the originally US-based biotech company MannKind Corporation, which has screened a total of about 200,000 chemical substances to find MKC8866. Professor Saatcioglus's research group has documented that MKC8866 counteracts the growth of prostate cancer tumors and shown that it interferes with a kind of chain reaction - a signaling pathway - that is associated with the cells' stress response." www.news-medical.net/news/20190124/Norwegian-scientists-discover-new-small-molecule-drug-to-treat-prostate-cancer.aspxDoes Mannkind still control the IP or was this transferred / sold off at some point? Al Mann used to tout how well the 2 cancer compounds he had in development worked... be a nice surprise if this can bring more market cap to the company.
|
|
|
|
Post by mannmade on Jan 24, 2019 12:32:23 GMT -5
My understanding is they were sold off for small milestone and royalty deal. Likely never going to get back in as start up would be too costly at this point as would have to start over.
|
|
|
|
Post by brentie on Jan 24, 2019 13:33:14 GMT -5
My understanding is they were sold off for small milestone and royalty deal. Likely never going to get back in as start up would be too costly at this point as would have to start over. I think this might be the one they are talking about. "Colby and MannKind Sign License and Joint Development Agreement to Develop and Commercialize Cancer Immunotherapy Products SAN JOSE, Calif. & VALENCIA, Calif.--(BUSINESS WIRE)--Nov. 13, 2012-- Colby Pharmaceutical Company and MannKind Corporation (Nasdaq: MNKD) today announced a license agreement granting Colby exclusive worldwide rights to develop and commercialize disease-specific antigen compounds and intra-lymph node delivery technologies from MannKind’s novel MKC1106 active immunotherapy programs, which are currently being developed for the treatment of melanoma, prostate, hematological disorders and other human cancers." www.investors.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-newsArticle&ID=1757920&highlight=Their other one was MKC204 (from 2013)... "Mannkind is developing its lead product, AFREZZA, an inhaled powder that is designed to be a quick acting insulin therapy. AFREZZA is in late stage clinical investigation for adults with both type 1 and type 2 diabetes for control of hyperglycemia. Additionally, the company is developing MKC1106-MT, an investigational cancer immunotherapy product, which is in Phase II clinical trials; and MKC204, which is in preclinical development stage for the treatment of malignancies and inflammatory diseases." |
|
|
|
Post by mnholdem on Jan 24, 2019 14:39:34 GMT -5
"...developed by the originally US-based biotech company MannKind Corporation ..." When did MannKind move out of the country?  |
|
/production/original_573352236.gif)
